“ VTE is one of the leading causes of maternal morbidity and mortality in Western
countries. Despite this, high quality data on how to manage pregnant women
with or at risk for VTE are limited and scattered amongst the obstetrical, general
hematology, and thrombosis literature. Our panel has gathered and synthesized
evidence to generate recommendations that cover the spectrum of questions
clinicians face about the diagnosis, prevention, and treatment of pregnancy-
associated VTE.” – Shannon Bates, MD, MSc – Chair, Pregnancy Panel
“ Hospital-acquired venous thrombosis is widely prevalent and accounts for a
large portion of all venous thrombosis cases. Certain types of ambulatory patients
are also at risk for thrombosis, including travelers, people in nursing homes, and the
elderly. The prevention panel sought to develop and address questions beyond
the hospital, and tackle some new topics that hadn’t been addressed before.” –
Mary Cushman, MD – Chair, Prophylaxis For Medical Patients Panel
CHAPTERS COMING SOON!
“ The thrombophilia chapter will aim to address questions around thrombophilia
testing in a rational fashion. For common scenarios for both inherited and
acquired thrombophilia, we will give recommendations for testing based on
estimates of numbers of patients who benefit and are harmed by testing and
subsequent use of anticoagulation to prevent VTE.” – Saskia Middeldorp, MD, PhD –
Chair, Thrombophilia Panel
“ Our panel will consider the major surgical areas in which VTE is high-risk,
particularly in the absence of preventive strategies. We will address questions
that cut across all surgical domains, comparing prevention tactics that
don’t necessarily relate to any one indication. – David R. Anderson, MD, – Chair,
Prophylaxis for Surgical Patients Panel
“ The cancer chapter will identify major questions that clinicians commonly face
with cancer patients at risk for VTE. We will capture the totality of evidence on
each of these questions and, based on that evidence, offer recommendations for
diagnosis and treatment.” – Gary Lyman, MD, MPH – Chair, Cancer Panel
“ The treatment panel will cover the entire spectrum of treatment and management —
from the time the diagnosis has been made until the clinician decides to end
treatment. Assessing the data from throughout this time, we will seek to answer
what the best therapies are for particular patients.” – Thomas Ortel, MD, PhD –
Chair, Treatment Panel